Celebrating our 10th anniversary – Unlock our special offer today

US government agencies have questioned the legality of cannabidiol (CBD) – just as the industry is starting to see the benefits of increased public awareness.

Actions by both the US Food and Drug Administration (FDA) and the US Drug Enforcement Administration (DEA) have recently cast doubt on the future of CBD, according to speakers at the Marijuana Business Conference (MJBizCon) held May 9th–11th in New Orleans.

The situation is further complicated by the lack of clarity over the status of CBD, as some stakeholders classify it as a drug and others as a dietary supplement. Speakers at the conference also discussed a potential loophole that would allow CBD to be legally sold as a product derived from industrial hemp.

Read full article
I'm already a subscriber
Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization